Role of nemonoxacin as a therapeutic option for community-acquired pneumonia in the era of atypical pathogens
Abstract
To systematically summarize the clinical data from phase II–IV studies of nemonoxacin malate and comprehensively evaluate the clinical efficacy of nemonoxacin in treating pneumonia caused by atypical pathogens, so as to inform empirical antimicrobial selection in clinical practice. A retrospective analysis was performed on the results of four phase II/III clinical studies of nemonoxacin malate in patients with community-acquired pneumonia (CAP) and on the composition and clinical outcomes of atypical pathogen–infected patients in one phase IV clinical study; subgroup efficacy analyses were conducted by age and by presence or absence of co-pathogen infection. This study included four phase II/III controlled trials and one phase IV single-arm trial, with a primary analysis population of 1769 CAP patients, of whom 994 were male (56.2%) and 775 were female (43.8%), with a mean age of 47.83 ± 16.39 years. In the phase II/III studies, 370 patients (27.8%) were positive for atypical pathogens, including Mycoplasma pneumoniae (MP) in 265 cases (19.9%), Chlamydia pneumoniae (CP) in 68 cases (5.1%), and Legionella pneumophila (LP) in 85 cases (6.4%). In the phase IV study, 172 patients (39.7%) were positive for atypical pathogens, including PM in 141 cases (32.6%), CP in 14 cases (3.2%), and LP in 50 cases (11.5%).Efficacy analysis showed that nemonoxacin 500 mg oral and injectable formulations had clinical success rates against atypical pathogens of 98.0% vs levofloxacin 95.5% (oral)…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets
- Molecular Epidemiology of mcr-1 -Positive Polymyxin B-Resistant Escherichia coli Producing Extended-Spectrum β-Lactamase (ESBL) in a Tertiary Hospital in Shandong, China
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.